论文信息 - Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16). - 字舞流文

Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16).

D. Niederwieser | C. Ludescher | W. Hilbe | W. Eisterer | J. Thaler

[1] J. Bennett,et al. Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia. , 1988, Blood.

[2] J. Adamson,et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. , 1987, The New England journal of medicine.

[3] E. Thiel,et al. Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukaemias. , 1985, European journal of cancer & clinical oncology.

[4] N. Nissen,et al. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial , 1984, Cancer treatment reports.

[5] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.